Episode Details
Back to Episodes
Roquefort Therapeutics Eyes $20B+ Oncology Opportunity with AO252 | Roquefort Therapeutics (LSE:ROQ)
Description
In this episode of The Watchlist, Ricki Lee speaks with Roquefort Therapeutics (LSE:ROQ) Incoming Chairman Sotirios Stergiopoulos about the company’s proposed acquisition of the exclusive worldwide license for AO252, a novel precision oncology asset.
Listeners will hear how AO252’s differentiated mechanism, ability to cross the blood-brain barrier, and early Phase 1 clinical signals could open the door to multiple cancer indications and a potential multi-billion-dollar market opportunity. The discussion also explores the upcoming milestones investors should watch as the clinical program advances.
This discussion covers:
- What makes AO252 a differentiated precision oncology asset
- The science behind its novel target and multi-mechanism approach
- Early Phase 1 clinical signals and safety profile
- Potential market opportunity across multiple solid tumor indications
- Key milestones investors should watch in the coming months
Website: https://www.roquefortplc.com
This podcast is made in partnership with Roquefort Therapeutics. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.